Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | F12 | P00748 | 7/20 | 0.34 |
| ▸ | MARS1 | P56192 | 1/20 | 0.33 |
| ▸ | APOL1 | O14791 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3729303 | 0.75 | APOL1 (0.32) | F12APOL1 | |
| SCHEMBL15717438 | 0.72 | TAS1R3 (0.40) | F12APOL1 | |
| SCHEMBL27821224 | 0.71 | — | — | |
| SCHEMBL15717294 | 0.70 | APOL1 (0.32) | APOL1 | |
| SCHEMBL19948657 | 0.68 | CYP11B1 (0.43) | — | |
| SCHEMBL1872257 | 0.65 | BDKRB1 (0.46) | — | |
| SCHEMBL22492459 | 0.65 | F12 (0.52) | F12 | |
| SCHEMBL784503 | 0.65 | CYP11B2 (0.36) | — | |
| SCHEMBL19973434 | 0.64 | TP53 (0.46) | — | |
| Hydrochloric Acid SCHEMBL1873147 | 0.64 | BDKRB1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231668-A1 | CONDENSED PENTACYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF FLAVIVIRIDAE INFECTIONS | GlaxoSmithKline LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090197856-A1 | ANTIVIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. | 2009-08-06 | — | — | US | disclosed |
| WO-2009086139-A1 | CONDENSED PENTACYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF FLAVIVIRIDAE INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197856-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, EIF2AK2, MAVS | SLC2A1 2177/4885F12 1075/4885MARS1 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.